By combining findings of poor patient prognosis for gliomas with heightened EGFR levels but low EFEMP1 expression, and by clarifying the EGFR-dependent nature of tumor suppression by EFEMP1, our data have provided a rational for low expression of EFEMP1 being a predictive factor for selecting patients who would benefit from anti-EGFR therapy. This evidence concerns the gene EGFR and glioma.